{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:35:13Z","timestamp":1792784113536,"version":"4.5.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2020B004"],"award-info":[{"award-number":["2020B004"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2020B004"],"award-info":[{"award-number":["2020B004"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dutch Heart Foundation together with Amarin, Novo Nordisk, Sanofi, Bayer and Daiichi Sankyo","award":["01-003-2023-0425"],"award-info":[{"award-number":["01-003-2023-0425"]}],"id":[{"id":"https:\/\/ror.org\/05nxhgm70","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["10140022210030"],"award-info":[{"award-number":["10140022210030"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The purpose of this review is to provide an overview of the current status of lipid-lowering therapy utilization and lipid goal attainment in women. We focus on lipid-lowering therapy in individuals with and without established atherosclerotic cardiovascular disease, as well as familial hypercholesterolemia. Additionally, this review aims to explore the underlying mechanisms driving these sex differences and to identify existing knowledge gaps in this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Despite the proven efficacy of lipid-lowering therapy in both sexes, real-world studies indicate that women with comparable risk profiles are less likely than men to receive these treatments. Furthermore, women who are prescribed statins typically receive lower-intensity regimens than men and are less likely to achieve guideline-recommended low-density lipoprotein cholesterol goals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Despite advancements in lipid-lowering therapies, women compared to men, are systematically undertreated. This difference is influenced by patient-related, physician-related, and societal factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-025-01275-1","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:14:59Z","timestamp":1738034099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women"],"prefix":"10.1007","volume":"27","author":[{"given":"Julie A. E.","family":"van Oortmerssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke W. C. M.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte F.","family":"van der Bijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben J. M.","family":"Mijnster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Kavousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine E.","family":"Roeters van Lennep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the IMPRESS consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"25","key":"1275_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1275_CR2","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153-639.","journal-title":"Circulation"},{"key":"1275_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pcad.2021.12.001","volume":"70","author":"LA Kaminsky","year":"2022","unstructured":"Kaminsky LA, German C, Imboden M, Ozemek C, Peterman JE, Brubaker PH. The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. Prog Cardiovasc Dis. 2022;70:8\u201315.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"1275_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS Jr, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension"},{"issue":"24","key":"1275_CR5","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"1275_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","volume":"121","author":"P Joseph","year":"2017","unstructured":"Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677\u201394.","journal-title":"Circ Res"},{"issue":"5","key":"1275_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","volume":"46","author":"S Barquera","year":"2015","unstructured":"Barquera S, Pedroza-Tobias A, Medina C, Hernandez-Barrera L, Bibbins-Domingo K, Lozano R, Moran AE. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328\u201338.","journal-title":"Arch Med Res"},{"issue":"2","key":"1275_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.004437","volume":"11","author":"NR Aggarwal","year":"2018","unstructured":"Aggarwal NR, Patel HN, Mehta LS, Sanghani RM, Lundberg GP, Lewis SJ, et al. Sex differences in ischemic heart disease: advances, obstacles, and next steps. Circ Cardiovasc Qual Outcomes. 2018;11(2): e004437.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"42","key":"1275_CR9","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","volume":"35","author":"M Nichols","year":"2014","unstructured":"Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2950\u20139.","journal-title":"Eur Heart J"},{"issue":"39","key":"1275_CR10","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1093\/eurheartj\/ehad472","volume":"44","author":"JE van Roeters","year":"2023","unstructured":"van Roeters JE, Tokgozoglu LS, Badimon L, Dumanski SM, Gulati M, Hess CN, et al. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European atherosclerosis society. Eur Heart J. 2023;44(39):4157\u201373.","journal-title":"Eur Heart J"},{"issue":"8","key":"1275_CR11","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jama.2009.1227","volume":"302","author":"JS Berger","year":"2009","unstructured":"Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, et al. Sex differences in mortality following acute coronary syndromes. JAMA. 2009;302(8):874\u201382.","journal-title":"JAMA"},{"issue":"1","key":"1275_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.amjcard.2006.01.048","volume":"98","author":"E Argulian","year":"2006","unstructured":"Argulian E, Patel AD, Abramson JL, Kulkarni A, Champney K, Palmer S, et al. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions. Am J Cardiol. 2006;98(1):48\u201353.","journal-title":"Am J Cardiol"},{"issue":"7533","key":"1275_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","volume":"332","author":"R Huxley","year":"2006","unstructured":"Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73\u20138.","journal-title":"BMJ"},{"issue":"2","key":"1275_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jacc.2017.05.024","volume":"70","author":"CN Bairey Merz","year":"2017","unstructured":"Bairey Merz CN, Andersen H, Sprague E, Burns A, Keida M, Walsh MN, et al. Knowledge, attitudes, and beliefs regarding cardiovascular disease in women: the Women\u2019s Heart Alliance. J Am Coll Cardiol. 2017;70(2):123\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1275_CR15","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1161\/CIR.0000000000000907","volume":"143","author":"M Cushman","year":"2021","unstructured":"Cushman M, Shay CM, Howard VJ, Jimenez MC, Lewey J, McSweeney JC, et al. Ten-year differences in women\u2019s awareness related to coronary heart disease: results of the 2019 American Heart Association national survey: a special report from the American Heart Association. Circulation. 2021;143(7):e239-48.","journal-title":"Circulation"},{"key":"1275_CR16","doi-asserted-by":"crossref","unstructured":"Redfors B, Angeras O, Ramunddal T, Petursson P, Haraldsson I, Dworeck C et al. Trends in gender differences in cardiac care and outcome after acute myocardial infarction in Western Sweden: a report from the Swedish web system for enhancement of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). J Am Heart Assoc. 2015;4(7):e001995.","DOI":"10.1161\/JAHA.115.001995"},{"issue":"8","key":"1275_CR17","doi-asserted-by":"publisher","first-page":"e005562","DOI":"10.1161\/CIRCOUTCOMES.118.005562","volume":"12","author":"MG Nanna","year":"2019","unstructured":"Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12(8):e005562.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"16","key":"1275_CR18","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.jacc.2018.02.032","volume":"71","author":"SAE Peters","year":"2018","unstructured":"Peters SAE, Colantonio LD, Zhao H, Bittner V, Dai Y, Farkouh ME, et al. Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol. 2018;71(16):1729\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1275_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/clc.22938","volume":"41","author":"JA Udell","year":"2018","unstructured":"Udell JA, Fonarow GC, Maddox TM, Cannon CP, Frank Peacock W, Laskey WK, et al. Sustained sex-based treatment differences in acute coronary syndrome care: insights from the American Heart Association get with the guidelines coronary artery disease registry. Clin Cardiol. 2018;41(6):758\u201368.","journal-title":"Clin Cardiol"},{"issue":"3","key":"1275_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055952","volume":"12","author":"RA Benson","year":"2022","unstructured":"Benson RA, Okoth K, Keerthy D, Gokhale K, Adderley NJ, Nirantharakumar K, Lasserson DS. Analysis of the relationship between sex and prescriptions for guideline-recommended therapy in peripheral arterial disease, in relation to 1-year all-cause mortality: a primary care cohort study. BMJ Open. 2022;12(3): e055952.","journal-title":"BMJ Open"},{"issue":"8","key":"1275_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1161\/CIRCRESAHA.116.307547","volume":"118","author":"M Garcia","year":"2016","unstructured":"Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118(8):1273\u201393.","journal-title":"Circ Res"},{"issue":"1","key":"1275_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.amjcard.2015.10.007","volume":"117","author":"MW Schoen","year":"2016","unstructured":"Schoen MW, Tabak RG, Salas J, Scherrer JF, Buckhold FR. Comparison of adherence to guideline-based cholesterol treatment goals in men versus women. Am J Cardiol. 2016;117(1):48\u201353.","journal-title":"Am J Cardiol"},{"issue":"40","key":"1275_CR23","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1093\/eurheartj\/ehv161","volume":"36","author":"GM Rosano","year":"2015","unstructured":"Rosano GM, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H, et al. Gender differences in the effect of cardiovascular drugs: a position document of the working group on pharmacology and drug therapy of the ESC. Eur Heart J. 2015;36(40):2677\u201380.","journal-title":"Eur Heart J"},{"issue":"32","key":"1275_CR24","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"25","key":"1275_CR25","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"9841","key":"1275_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"C Cholesterol Treatment Trialists","year":"2012","unstructured":"Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"24","key":"1275_CR27","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330.","journal-title":"Eur Heart J"},{"issue":"1","key":"1275_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"14","key":"1275_CR29","first-page":"e698","volume":"139","author":"KK Stout","year":"2019","unstructured":"Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, et al. 2018 AHA\/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Circulation. 2019;139(14):e698-800.","journal-title":"Circulation"},{"issue":"9976","key":"1275_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"C Cholesterol Treatment Trialists","year":"2015","unstructured":"Cholesterol Treatment Trialists C, Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"11","key":"1275_CR31","doi-asserted-by":"publisher","first-page":"e014742","DOI":"10.1161\/JAHA.119.014742","volume":"9","author":"M Zhao","year":"2020","unstructured":"Zhao M, Woodward M, Vaartjes I, Millett ERC, Klipstein-Grobusch K, Hyun K, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(11):e014742.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"1275_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/heartjnl-2023-323722","volume":"110","author":"PAJ Kiss","year":"2024","unstructured":"Kiss PAJ, Uijl A, de Boer AR, Duk TCX, Grobbee DE, Hollander M, et al. Sex differences in the intensity of statin prescriptions at initiation in a primary care setting. Heart. 2024;110(15):981\u20137.","journal-title":"Heart"},{"issue":"1","key":"1275_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.amjcard.2014.09.041","volume":"115","author":"SS Virani","year":"2015","unstructured":"Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, et al. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015;115(1):21\u20136.","journal-title":"Am J Cardiol"},{"issue":"7","key":"1275_CR34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.119.043731","volume":"141","author":"S Xia","year":"2020","unstructured":"Xia S, Du X, Guo L, Du J, Arnott C, Lam CSP, et al. Sex differences in primary and secondary prevention of cardiovascular disease in China. Circulation. 2020;141(7):530\u20139.","journal-title":"Circulation"},{"issue":"1","key":"1275_CR35","doi-asserted-by":"publisher","first-page":"e001900","DOI":"10.1136\/openhrt-2021-001900","volume":"9","author":"SH Bots","year":"2022","unstructured":"Bots SH, Onland-Moret NC, Jancev M, Hollander M, Tulevski II, Hofstra L et al. Statins are associated with a large reduction in all-cause mortality in women from a cardiac outpatient population. Open Heart. 2022;9(1):e001900.","journal-title":"Open Heart"},{"issue":"18","key":"1275_CR36","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","volume":"79","author":"AJ Nelson","year":"2022","unstructured":"Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79(18):1802\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"1275_CR37","doi-asserted-by":"publisher","first-page":"117148","DOI":"10.1016\/j.atherosclerosis.2023.05.017","volume":"384","author":"C Gavina","year":"2023","unstructured":"Gavina C, Araujo F, Teixeira C, Ruivo JA, Corte-Real AL, Luz-Duarte L, et al. Sex differences in LDL-C control in a primary care population: the PORTRAIT-DYS study. Atherosclerosis. 2023;384:117148.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1275_CR38","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jacl.2014.12.003","volume":"9","author":"G Mombelli","year":"2015","unstructured":"Mombelli G, Bosisio R, Calabresi L, Magni P, Pavanello C, Pazzucconi F, Sirtori CR. Gender-related lipid and\/or lipoprotein responses to statins in subjects in primary and secondary prevention. J Clin Lipidol. 2015;9(2):226\u201333.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1275_CR39","doi-asserted-by":"publisher","first-page":"e2251156","DOI":"10.1001\/jamanetworkopen.2022.51156","volume":"6","author":"A Mufarreh","year":"2023","unstructured":"Mufarreh A, Shah AJ, Vaccarino V, Kulshreshtha A. Trends in provision of medications and lifestyle counseling in ambulatory settings by gender and race for patients with atherosclerotic cardiovascular disease, 2006\u20132016. JAMA Netw Open. 2023;6(1):e2251156.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1275_CR40","doi-asserted-by":"publisher","first-page":"e004264","DOI":"10.1161\/JAHA.116.004264","volume":"6","author":"CM Gamboa","year":"2017","unstructured":"Gamboa CM, Colantonio LD, Brown TM, Carson AP, Safford MM. Race-sex differences in statin use and low-density lipoprotein cholesterol control among people with diabetes mellitus in the reasons for geographic and racial differences in stroke study. J Am Heart Assoc. 2017;6(5):e004264.","journal-title":"J Am Heart Assoc"},{"key":"1275_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.08.070","volume":"161","author":"G Metser","year":"2021","unstructured":"Metser G, Bradley C, Moise N, Liyanage-Don N, Kronish I, Ye S. Gaps and disparities in primary prevention statin prescription during outpatient care. Am J Cardiol. 2021;161:36\u201341.","journal-title":"Am J Cardiol"},{"key":"1275_CR42","doi-asserted-by":"publisher","first-page":"100496","DOI":"10.1016\/j.ajpc.2023.100496","volume":"14","author":"C Witting","year":"2023","unstructured":"Witting C, Azizi Z, Gomez SE, Zammit A, Sarraju A, Ngo S, et al. Natural language processing to identify reasons for sex disparity in statin prescriptions. Am J Prev Cardiol. 2023;14:100496.","journal-title":"Am J Prev Cardiol"},{"key":"1275_CR43","doi-asserted-by":"publisher","first-page":"100667","DOI":"10.1016\/j.ajpc.2024.100667","volume":"18","author":"A Koczo","year":"2024","unstructured":"Koczo A, Brickshawana A, Zhu J, Thoma F, Countouris M, Berlacher K, et al. Sex-based utilization of guideline recommended statin therapy and cardiovascular disease outcomes: data from a multisite healthcare network primary prevention cohort. Am J Prev Cardiol. 2024;18:100667.","journal-title":"Am J Prev Cardiol"},{"key":"1275_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.phrs.2016.12.027","volume":"117","author":"R Cangemi","year":"2017","unstructured":"Cangemi R, Romiti GF, Campolongo G, Ruscio E, Sciomer S, Gianfrilli D, Raparelli V. Gender related differences in treatment and response to statins in primary and secondary cardiovascular prevention: the never-ending debate. Pharmacol Res. 2017;117:148\u201355.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1275_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.amjcard.2014.11.026","volume":"115","author":"PY Hsue","year":"2015","unstructured":"Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, Wenger NK, Waters DD. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Am J Cardiol. 2015;115(4):447\u201353.","journal-title":"Am J Cardiol"},{"issue":"8","key":"1275_CR46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.numecd.2018.03.012","volume":"28","author":"S Moreno-Arellano","year":"2018","unstructured":"Moreno-Arellano S, Delgado-de-Mendoza J, Santi-Cano MJ. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men. Nutr Metab Cardiovasc Dis. 2018;28(8):810\u20135.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"9","key":"1275_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"S Mora","year":"2010","unstructured":"Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the justification for the Use of statins in Prevention: an intervention trial evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069\u201377.","journal-title":"Circulation"},{"issue":"1","key":"1275_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.whi.2014.09.004","volume":"25","author":"J Billimek","year":"2015","unstructured":"Billimek J, Malik S, Sorkin DH, Schmalbach P, Ngo-Metzger Q, Greenfield S, Kaplan SH. Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence after treatment intensification. Womens Health Issues. 2015;25(1):6\u201312.","journal-title":"Womens Health Issues"},{"issue":"5","key":"1275_CR49","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ahj.2013.02.011","volume":"165","author":"J Lewey","year":"2013","unstructured":"Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165(5):665\u201378 78 e1.","journal-title":"Am Heart J"},{"issue":"4","key":"1275_CR50","doi-asserted-by":"publisher","first-page":"e228224","DOI":"10.1001\/jamanetworkopen.2022.8224","volume":"5","author":"SH Bots","year":"2022","unstructured":"Bots SH, Schreuder MM, van Roeters JE, Watson S, van Puijenbroek E, Onland-Moret NC, den Ruijter HM. Sex differences in reported adverse drug reactions to angiotensin-converting enzyme inhibitors. JAMA Netw Open. 2022;5(4):e228224.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"1275_CR51","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140(11):e596-646.","journal-title":"Circulation"},{"issue":"10170","key":"1275_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"C Cholesterol Treatment Trialists","year":"2019","unstructured":"Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407\u201315.","journal-title":"Lancet"},{"issue":"1","key":"1275_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2020.7848","volume":"324","author":"AR Orkaby","year":"2020","unstructured":"Orkaby AR, Driver JA, Ho YL, Lu B, Costa L, Honerlaw J, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020;324(1):68\u201378.","journal-title":"JAMA"},{"key":"1275_CR54","doi-asserted-by":"crossref","unstructured":"Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004;5(3):81\u20137.","DOI":"10.1016\/j.atherosclerosissup.2004.08.027"},{"issue":"13","key":"1275_CR55","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138.","journal-title":"JAMA"},{"issue":"14","key":"1275_CR56","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"25","key":"1275_CR57","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"7","key":"1275_CR58","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/heartjnl-2018-313959","volume":"105","author":"C Wilkinson","year":"2019","unstructured":"Wilkinson C, Bebb O, Dondo TB, Munyombwe T, Casadei B, Clarke S, et al. Sex differences in quality indicator attainment for myocardial infarction: a nationwide cohort study. Heart. 2019;105(7):516\u201323.","journal-title":"Heart"},{"issue":"24","key":"1275_CR59","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/heartjnl-2019-315134","volume":"105","author":"CMY Lee","year":"2019","unstructured":"Lee CMY, Mnatzaganian G, Woodward M, Chow CK, Sitas F, Robinson S, Huxley RR. Sex disparities in the management of coronary heart disease in general practices in Australia. Heart. 2019;105(24):1898\u2013904.","journal-title":"Heart"},{"issue":"7","key":"1275_CR60","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jamacardio.2021.0683","volume":"6","author":"MT Lee","year":"2021","unstructured":"Lee MT, Mahtta D, Ramsey DJ, Liu J, Misra A, Nasir K, et al. Sex-related disparities in cardiovascular health care among patients with premature atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021;6(7):782\u201390.","journal-title":"JAMA Cardiol"},{"key":"1275_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2021.101342","volume":"22","author":"E Barrett","year":"2021","unstructured":"Barrett E, Paige E, Welsh J, Korda RJ, Joshy G, Martin M, Banks E. Differences between men and women in the use of preventive medications following a major cardiovascular event: Australian prospective cohort study. Prev Med Rep. 2021;22: 101342.","journal-title":"Prev Med Rep"},{"key":"1275_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2023.05.007","volume":"375","author":"L Kuehnemund","year":"2023","unstructured":"Kuehnemund L, Lange SA, Feld J, Padberg JS, Fischer AJ, Makowski L, et al. Sex disparities in guideline-recommended therapies and outcomes after ST-elevation myocardial infarction in a contemporary nationwide cohort of patients over an eight-year period. Atherosclerosis. 2023;375:30\u20137.","journal-title":"Atherosclerosis"},{"issue":"7","key":"1275_CR63","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","volume":"43","author":"P Guedeney","year":"2022","unstructured":"Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(7):e17-25.","journal-title":"Eur Heart J"},{"issue":"12","key":"1275_CR64","doi-asserted-by":"publisher","first-page":"e006910","DOI":"10.1161\/JAHA.117.006910","volume":"6","author":"A Karatasakis","year":"2017","unstructured":"Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a Meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017;6(12):e006910.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1275_CR65","doi-asserted-by":"publisher","first-page":"e016839","DOI":"10.1161\/JAHA.120.016839","volume":"10","author":"ML Daviglus","year":"2021","unstructured":"Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein b, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies. J Am Heart Assoc. 2021;10(1):e016839.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"1275_CR66","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1275_CR67","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"22","key":"1275_CR68","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"8","key":"1275_CR69","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/2047487320902750","volume":"28","author":"P Sever","year":"2021","unstructured":"Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial. Eur J Prev Cardiol. 2021;28(8):805\u201312.","journal-title":"Eur J Prev Cardiol"},{"key":"1275_CR70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vph.2019.03.002","volume":"116","author":"T Hollstein","year":"2019","unstructured":"Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, Marz W, Laufs U, et al. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Vascul Pharmacol. 2019;116:8\u201315.","journal-title":"Vascul Pharmacol"},{"issue":"9","key":"1275_CR71","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/03007995.2020.1786678","volume":"36","author":"DR Leitner","year":"2020","unstructured":"Leitner DR, Toplak H, Kedenko L, Steinmaurer T, Graff V, Metzner T, et al. Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study. Curr Med Res Opin. 2020;36(9):1419\u201325.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1275_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/FJC.0000000000001205","volume":"79","author":"A Cordero","year":"2022","unstructured":"Cordero A, Fernandez Del Olmo MR, Cortez Quiroga GA, Romero-Menor C, Facila L, Seijas-Amigo J, et al. Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry. J Cardiovasc Pharmacol. 2022;79(4):523\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1275_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112519","volume":"146","author":"J Vicente-Valor","year":"2022","unstructured":"Vicente-Valor J, Garcia-Gonzalez X, Ibanez-Garcia S, Duran-Garcia ME, de Lorenzo-Pinto A, Rodriguez-Gonzalez C, et al. PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort. Biomed Pharmacother. 2022;146: 112519.","journal-title":"Biomed Pharmacother"},{"key":"1275_CR74","doi-asserted-by":"publisher","first-page":"117108","DOI":"10.1016\/j.atherosclerosis.2023.03.013","volume":"384","author":"AMH Galema-Boers","year":"2023","unstructured":"Galema-Boers AMH, Mulder J, Steward K, Roeters van Lennep JE. Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry. Atherosclerosis. 2023;384:117108.","journal-title":"Atherosclerosis"},{"issue":"9","key":"1275_CR75","doi-asserted-by":"publisher","first-page":"100669","DOI":"10.1016\/j.jacadv.2023.100669","volume":"2","author":"FB Rivera","year":"2023","unstructured":"Rivera FB, Cha SW, Aparece JP, Rocimo A, Ong BA, Golbin JM, et al. Sex differences in cardiovascular outcomes and cholesterol-lowering efficacy of PCSK9 inhibitors: systematic review and meta-analysis. JACC Adv. 2023;2(9):100669.","journal-title":"JACC Adv"},{"key":"1275_CR76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","volume":"309","author":"N Ferri","year":"2020","unstructured":"Ferri N, Ruscica M, Coggi D, Bonomi A, Amato M, Frigerio B, et al. Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study. Atherosclerosis. 2020;309:39\u201346.","journal-title":"Atherosclerosis"},{"key":"1275_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.953845","volume":"13","author":"F Jia","year":"2022","unstructured":"Jia F, Fei SF, Tong DB, Xue C, Li JJ. Sex difference in circulating PCSK9 and its clinical implications. Front Pharmacol. 2022;13: 953845.","journal-title":"Front Pharmacol"},{"key":"1275_CR78","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fendo.2019.00930","volume":"10","author":"W Fu","year":"2019","unstructured":"Fu W, Gao XP, Zhang S, Dai YP, Zou WJ, Yue LM. 17beta-Estradiol inhibits PCSK9-Mediated LDLR degradation through GPER\/PLC activation in HepG2 cells. Front Endocrinol (Lausanne). 2019;10:930.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1275_CR79","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1194\/jlr.M055780","volume":"56","author":"M Ghosh","year":"2015","unstructured":"Ghosh M, Galman C, Rudling M, Angelin B. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res. 2015;56(2):463\u20139.","journal-title":"J Lipid Res"},{"issue":"20","key":"1275_CR80","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1275_CR81","doi-asserted-by":"publisher","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","DOI":"10.1093\/eurheartj\/ehz455"},{"issue":"16","key":"1275_CR82","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","volume":"381","author":"IK Luirink","year":"2019","unstructured":"Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547\u201356.","journal-title":"N Engl J Med"},{"key":"1275_CR83","doi-asserted-by":"crossref","unstructured":"Iatan I, Akioyamen LE, Ruel I, Guerin A, Hales L, Coutinho T et al. Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis. Eur Heart J. 2024;45(35):3231-3250.","DOI":"10.1093\/eurheartj\/ehae417"},{"key":"1275_CR84","unstructured":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).. Lancet. 2021;398(10312):1713\u201325."},{"key":"1275_CR85","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.athplu.2023.06.001","volume":"53","author":"W M\u00e4rz","year":"2023","unstructured":"M\u00e4rz W, Schmidt N, An Haack I, Dressel A, Grammer TB, Kleber ME, et al. The German CaRe high registry for familial hypercholesterolemia - sex differences, treatment strategies, and target value attainment. Atheroscler Plus. 2023;53:6\u201315.","journal-title":"Atheroscler Plus"},{"key":"1275_CR86","doi-asserted-by":"crossref","unstructured":"de Isla LP, Vallejo-Vaz AJ, Watts GF, Mu\u00f1iz-Grijalvo O, Alonso R, Diaz-Diaz JL et al. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study. Lancet Diabetes Endocrinol. 2024;12(9):643-652.","DOI":"10.1016\/S2213-8587(24)00192-X"},{"issue":"1","key":"1275_CR87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jacl.2020.12.001","volume":"15","author":"R Mehta","year":"2021","unstructured":"Mehta R, Martagon AJ, Galan Ramirez GA, Antonio-Villa NE, Vargas-V\u00e1zquez A, Elias-Lopez D, et al. Familial hypercholesterolemia in Mexico: initial insights from the national registry. J Clin Lipidol. 2021;15(1):124\u201333.","journal-title":"J Clin Lipidol"},{"key":"1275_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2023.110649","volume":"120","author":"S Faubert","year":"2023","unstructured":"Faubert S, Paquette M, Baass A, Bernard S. Treatment target achievement in patients with familial hypercholesterolemia: a real-world descriptive study. Clin Biochem. 2023;120: 110649.","journal-title":"Clin Biochem"},{"key":"1275_CR89","doi-asserted-by":"crossref","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M et al. 2023 Update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291.","DOI":"10.1093\/eurheartj\/ehad197"},{"key":"1275_CR90","doi-asserted-by":"crossref","unstructured":"Mulder J, Tromp TR, Al-Khnifsawi M, Blom DJ, Chlebus K, Cuchel M, et al. Sex differences in diagnosis, treatment, and cardiovascular outcomes in homozygous familial hypercholesterolemia. JAMA Cardiol. 2024;9(4):313-322.","DOI":"10.1001\/jamacardio.2023.5597"},{"issue":"17","key":"1275_CR91","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"2","key":"1275_CR92","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL II, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"33","key":"1275_CR93","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.2174\/138161211798220891","volume":"17","author":"YH Gomez Sandoval","year":"2011","unstructured":"Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17(33):3669\u201389.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1275_CR94","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684\u201398.","journal-title":"Br J Clin Pharmacol"},{"key":"1275_CR95","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","volume":"225","author":"M Banach","year":"2016","unstructured":"Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184\u201396.","journal-title":"Int J Cardiol"},{"issue":"11","key":"1275_CR96","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","volume":"37","author":"SF Nielsen","year":"2016","unstructured":"Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37(11):908\u201316.","journal-title":"Eur Heart J"},{"issue":"8","key":"1275_CR97","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","volume":"68","author":"S Bansilal","year":"2016","unstructured":"Bansilal S, Castellano JM, Garrido E, Wei HG, Freeman A, Spettell C, et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol. 2016;68(8):789\u2013801.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1275_CR98","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361\u201375.","journal-title":"J Clin Lipidol"},{"key":"1275_CR99","unstructured":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832\u201345."},{"issue":"34","key":"1275_CR100","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323.","journal-title":"Eur Heart J"},{"issue":"3","key":"1275_CR101","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5551\/jat.RV17030","volume":"26","author":"R Alonso","year":"2019","unstructured":"Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance. J Atheroscler Thromb. 2019;26(3):207\u201315.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"1275_CR102","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","volume":"10","author":"DG Karalis","year":"2016","unstructured":"Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, Cohen JD. Gender differences in side effects and attitudes regarding statin use in the understanding statin use in America and gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10(4):833\u201341.","journal-title":"J Clin Lipidol"},{"key":"1275_CR103","first-page":"47","volume":"8","author":"S Bhardwaj","year":"2013","unstructured":"Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47\u201359.","journal-title":"Clin Interv Aging"},{"key":"1275_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","volume":"83","author":"GD Anderson","year":"2008","unstructured":"Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1\u201310.","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"1275_CR105","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SC Group","year":"2008","unstructured":"Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. N Engl J Med. 2008;359(8):789\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"1275_CR106","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","volume":"80","author":"M Niemi","year":"2006","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80(4):356\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1275_CR107","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jpain.2008.12.001","volume":"10","author":"RB Fillingim","year":"2009","unstructured":"Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL III. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10(5):447\u201385.","journal-title":"J Pain"},{"key":"1275_CR108","doi-asserted-by":"publisher","first-page":"n135","DOI":"10.1136\/bmj.n135","volume":"372","author":"E Herrett","year":"2021","unstructured":"Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135.","journal-title":"BMJ"},{"issue":"12","key":"1275_CR109","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","volume":"78","author":"JP Howard","year":"2021","unstructured":"Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1275_CR110","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMc2031173","volume":"383","author":"FA Wood","year":"2020","unstructured":"Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182\u20134.","journal-title":"N Engl J Med"},{"issue":"5","key":"1275_CR111","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.287.5.622","volume":"287","author":"AJ Barsky","year":"2002","unstructured":"Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622\u20137.","journal-title":"JAMA"},{"issue":"12","key":"1275_CR112","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1037\/hea0000416","volume":"35","author":"RK Webster","year":"2016","unstructured":"Webster RK, Weinman J, Rubin GJ. A systematic review of factors that contribute to nocebo effects. Health Psychol. 2016;35(12):1334\u201355.","journal-title":"Health Psychol"},{"issue":"18","key":"1275_CR113","doi-asserted-by":"publisher","first-page":"e009221","DOI":"10.1161\/JAHA.118.009221","volume":"7","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, et al. Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials. J Am Heart Assoc. 2018;7(18):e009221.","journal-title":"J Am Heart Assoc"},{"key":"1275_CR114","doi-asserted-by":"crossref","unstructured":"Bittner VA, Schwartz GG, Bhatt DL, Chua T, De Silva HA, Diaz R, et al. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. J Clin Lipidol. 2024;18(4):e548-e561.","DOI":"10.1016\/j.jacl.2024.04.122"},{"key":"1275_CR115","doi-asserted-by":"publisher","unstructured":"Wright RS, Ray KK, Landmesser U, Koenig W, Raal FJ, Leiter LA, Conde LG, Han J, Schwartz GG. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials. Mayo Clin Proc. 2024;S0025\u20136196(24)00167\u20138. https:\/\/doi.org\/10.1016\/j.mayocp.2024.03.025.","DOI":"10.1016\/j.mayocp.2024.03.025"},{"issue":"2","key":"1275_CR116","doi-asserted-by":"publisher","first-page":"e231047","DOI":"10.1001\/jamanetworkopen.2023.1047","volume":"6","author":"CJ Brown","year":"2023","unstructured":"Brown CJ, Chang LS, Hosomura N, Malmasi S, Morrison F, Shubina M, et al. Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk. JAMA Netw Open. 2023;6(2):e231047.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1275_CR117","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacl.2017.02.013","volume":"11","author":"R Silvennoinen","year":"2017","unstructured":"Silvennoinen R, Turunen JH, Kovanen PT, Syv\u00e4nne M, Tikkanen MJ. Attitudes and actions: a survey to assess statin use among Finnish patients with increased risk for cardiovascular events. J Clin Lipidol. 2017;11(2):485\u201394.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1275_CR118","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.jacl.2023.10.007","volume":"18","author":"B Alshibani","year":"2024","unstructured":"Alshibani B, Iatan I, Guerin A, Ruel I, Cermakova L, Ramanakumar AV, et al. Sex differences in the perception of cardiovascular risk in familial hypercholesterolemia. J Clin Lipidol. 2024;18(1):e97-104.","journal-title":"J Clin Lipidol"},{"key":"1275_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104514","volume":"155","author":"E Olmastroni","year":"2020","unstructured":"Olmastroni E, Boccalari MT, Tragni E, Rea F, Merlino L, Corrao G, et al. Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies. Pharmacol Res. 2020;155: 104514.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1275_CR120","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/2047487317744363","volume":"25","author":"DC Eindhoven","year":"2018","unstructured":"Eindhoven DC, Hilt AD, Zwaan TC, Schalij MJ, Borleffs CJW. Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment - the Netherlands claims database. Eur J Prev Cardiol. 2018;25(2):181\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"1275_CR121","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ejvs.2022.02.007","volume":"63","author":"D Messiha","year":"2022","unstructured":"Messiha D, Petrikhovich O, Lortz J, Mahabadi AA, Hering R, Schulz M, et al. Gender differences in outpatient peripheral artery disease management in Germany: a population based study 2009\u20132018. Eur J Vasc Endovasc Surg. 2022;63(5):714\u201320.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"1275_CR122","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-022-01495-8","volume":"21","author":"ML Morieri","year":"2022","unstructured":"Morieri ML, Lamacchia O, Manzato E, Giaccari A, Avogaro A. Physicians\u2019 misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovasc Diabetol. 2022;21(1):57.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1275_CR123","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s11606-021-07191-9","volume":"37","author":"J Yu","year":"2022","unstructured":"Yu J, Wang AA, Zimmerman LP, Deng Y, Vu TT, Tedla YG, et al. A cohort analysis of statin treatment patterns among small-sized primary care practices. J Gen Intern Med. 2022;37(8):1845\u201352.","journal-title":"J Gen Intern Med"},{"key":"1275_CR124","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.atherosclerosis.2023.04.013","volume":"375","author":"J Cos\u00edn-Sales","year":"2023","unstructured":"Cos\u00edn-Sales J, Campuzano Ruiz R, D\u00edaz D\u00edaz JL, Escobar Cervantes C, Fern\u00e1ndez Olmo MR, G\u00f3mez-Doblas JJ, et al. Impact of physician\u2019s perception about LDL cholesterol control in clinical practice when treating patients in Spain. Atherosclerosis. 2023;375:38\u201344.","journal-title":"Atherosclerosis"},{"issue":"14","key":"1275_CR125","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/eurjpc\/zwac103","volume":"29","author":"MD Chobufo","year":"2022","unstructured":"Chobufo MD, Regner SR, Zeb I, Lacoste JL, Virani SS, Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017\u20132020. Eur J Prev Cardiol. 2022;29(14):1830\u20138.","journal-title":"Eur J Prev Cardiol"},{"key":"1275_CR126","doi-asserted-by":"crossref","unstructured":"Agapito I, Hoang T, Sayer M, Naqvi A, Patel PM, Ozaki AF. Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure. J Am Med Inf Assoc. 2024;31(12):2924-2931.","DOI":"10.1093\/jamia\/ocae203"},{"issue":"5","key":"1275_CR127","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jacl.2019.06.008","volume":"13","author":"CK Bradley","year":"2019","unstructured":"Bradley CK, Shrader P, Sanchez RJ, Peterson ED, Navar AM. The patient journey with proprotein convertase subtilisin\/kexin type 9 inhibitors in community practice. J Clin Lipidol. 2019;13(5):725\u201334.","journal-title":"J Clin Lipidol"},{"issue":"20","key":"1275_CR128","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/heartjnl-2017-311429","volume":"103","author":"M Zhao","year":"2017","unstructured":"Zhao M, Vaartjes I, Graham I, Grobbee D, Spiering W, Klipstein-Grobusch K, et al. Sex differences in risk factor management of coronary heart disease across three regions. Heart. 2017;103(20):1587\u201394.","journal-title":"Heart"},{"issue":"9","key":"1275_CR129","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2019.2481","volume":"4","author":"V Bittner","year":"2019","unstructured":"Bittner V, Colantonio LD, Dai Y, Woodward M, Mefford MT, Rosenson RS, et al. Association of region and hospital and patient characteristics with use of high-intensity statins after myocardial infarction among medicare beneficiaries. JAMA Cardiol. 2019;4(9):865\u201372.","journal-title":"JAMA Cardiol"},{"key":"1275_CR130","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2147\/PPA.S133168","volume":"11","author":"M Kriegbaum","year":"2017","unstructured":"Kriegbaum M, Liisberg KB, Wallach-Kildemoes H. Pattern of statin use changes following media coverage of its side effects. Patient Prefer Adherence. 2017;11:1151\u20137.","journal-title":"Patient Prefer Adherence"},{"key":"1275_CR131","doi-asserted-by":"publisher","first-page":"i3283","DOI":"10.1136\/bmj.i3283","volume":"353","author":"A Matthews","year":"2016","unstructured":"Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, Bhaskaran K. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.","journal-title":"BMJ"},{"issue":"11","key":"1275_CR132","doi-asserted-by":"publisher","first-page":"591","DOI":"10.5694\/mja15.00103","volume":"202","author":"AL Schaffer","year":"2015","unstructured":"Schaffer AL, Buckley NA, Dobbins TA, Banks E, Pearson SA. The crux of the matter: did the ABC\u2019s Catalyst program change statin use in Australia? Med J Aust. 2015;202(11):591\u20135.","journal-title":"Med J Aust"},{"issue":"10292","key":"1275_CR133","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","volume":"397","author":"B Vogel","year":"2021","unstructured":"Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385\u2013438.","journal-title":"Lancet"},{"issue":"18","key":"1275_CR134","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","volume":"71","author":"PE Scott","year":"2018","unstructured":"Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, et al. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. J Am Coll Cardiol. 2018;71(18):1960\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1275_CR135","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.119.043594","volume":"141","author":"X Jin","year":"2020","unstructured":"Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women\u2019s participation in cardiovascular clinical trials from 2010 to 2017. Circulation. 2020;141(7):540\u20138.","journal-title":"Circulation"},{"issue":"5","key":"1275_CR136","doi-asserted-by":"publisher","first-page":"e205202","DOI":"10.1001\/jamanetworkopen.2020.5202","volume":"3","author":"SU Khan","year":"2020","unstructured":"Khan SU, Khan MZ, Raghu Subramanian C, Riaz H, Khan MU, Lone AN, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. JAMA Netw Open. 2020;3(5):e205202.","journal-title":"JAMA Netw Open"},{"issue":"14","key":"1275_CR137","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/NEJMp2215609","volume":"388","author":"AL Schwartz","year":"2023","unstructured":"Schwartz AL, Alsan M, Morris AA, Halpern SD. Why diverse clinical trial participation matters. N Engl J Med. 2023;388(14):1252\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"1275_CR138","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143\u201357.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1275_CR139","doi-asserted-by":"publisher","first-page":"e020663","DOI":"10.1161\/JAHA.121.020663","volume":"10","author":"C Raghu Subramanian","year":"2021","unstructured":"Raghu Subramanian C, Khan SU, Lone AN, Reza N, DeFilippis EM, Gulati M, Michos ED. Representation of women authors in trials of lipid-lowering therapy. J Am Heart Assoc. 2021;10(11):e020663.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"1275_CR140","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jamainternmed.2023.5104","volume":"183","author":"I Waldhorn","year":"2023","unstructured":"Waldhorn I, Bomze D, Ben-Aharon I, Schlosser S, Markel G, Ludmir EB, Meirson T. Gender gap in leadership of clinical trials. JAMA Intern Med. 2023;183(12):1406\u20138.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1275_CR141","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/jamainternmed.2019.0907","volume":"179","author":"KL Hart","year":"2019","unstructured":"Hart KL, Perlis RH. Trends in proportion of women as authors of medical journal articles, 2008\u20132018. JAMA Intern Med. 2019;179(9):1285\u20137.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1275_CR142","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.gie.2015.01.032","volume":"81","author":"MT Long","year":"2015","unstructured":"Long MT, Leszczynski A, Thompson KD, Wasan SK, Calderwood AH. Female authorship in major academic gastroenterology journals: a look over 20 years. Gastrointest Endosc. 2015;81(6):1440-7.e3.","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"1275_CR143","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006605","volume":"13","author":"N Reza","year":"2020","unstructured":"Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, et al. Representation of women authors in international Heart failure guidelines and contemporary clinical trials. Circ Heart Fail. 2020;13(8): e006605.","journal-title":"Circ Heart Fail"},{"key":"1275_CR144","doi-asserted-by":"publisher","unstructured":"Matthews S, Cook S, Clayton T, Murray S, Wynne R, Sanders J. Factors affecting women's participation in cardiovascular research: a scoping review. Eur J Cardiovasc Nurs. 2024;23(2):107\u2013114. https:\/\/doi.org\/10.1093\/eurjcn\/zvad048.","DOI":"10.1093\/eurjcn\/zvad048"},{"issue":"9","key":"1275_CR145","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archinte.167.9.905","volume":"167","author":"EL Ding","year":"2007","unstructured":"Ding EL, Powe NR, Manson JE, Sherber NS, Braunstein JB. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med. 2007;167(9):905\u201312.","journal-title":"Arch Intern Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01275-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T15:02:55Z","timestamp":1738076575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01275-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01275-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"3 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Jeanine Roeters van Lennep received a grant from Novartis that was paid to the institution. This funding source had no role in writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"29"}}